Diethylstilbestrol
Stilbestrol, Stilbetin, Stilphostrol (diethylstilbestrol) is a small molecule pharmaceutical. Diethylstilbestrol was first approved as Stilbestrol on 1982-01-01. It is used to treat breast neoplasms, carcinoma, and prostatic neoplasms in the USA. The pharmaceutical is active against estrogen receptor. In addition, it is known to target estrogen-related receptor gamma, steroid hormone receptor ERR2, steroid hormone receptor ERR1, and estrogen receptor beta.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Diethylstilbestrol
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| STILBESTROL | Bristol Myers Squibb | N-004056 DISCN | 1982-01-01 | 6 products |
| STILBETIN | Bristol Myers Squibb | N-004056 DISCN | 1982-01-01 | 9 products |
| DIETHYLSTILBESTROL | Eli Lilly | N-004039 DISCN | 1982-01-01 | 5 products |
| DIETHYLSTILBESTROL | Eli Lilly | N-004040 DISCN | 1982-01-01 | 2 products |
| DIETHYLSTILBESTROL | Eli Lilly | N-004041 DISCN | 1982-01-01 | 4 products |
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| prostatic neoplasms | — | D011471 | C61 |
| carcinoma | — | D002277 | C80.0 |
| breast neoplasms | EFO_0003869 | D001943 | C50 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
G: Genito urinary system and sex hormones
— G03: Sex hormones and modulators of the genital system
— G03C: Estrogens, sex hormones and modulators of the genital system
— G03CB: Synthetic estrogens, plain
— G03CB02: Diethylstilbestrol
— G03CC: Estrogens, combinations with other drugs
— G03CC05: Diethylstilbestrol
L: Antineoplastic and immunomodulating agents
— L02: Endocrine therapy antineoplastic and immunomodulating agents
— L02A: Hormones and related agents
— L02AA: Estrogens, endocrine therapy drugs
— L02AA01: Diethylstilbestrol
HCPCS
Code | Description |
|---|---|
| J9165 | Injection, diethylstilbestrol diphosphate, 250 mg |
Clinical
Clinical Trials
7 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Prostatic neoplasms | D011471 | — | C61 | — | 2 | 2 | — | 1 | 5 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | — | — | 1 | — | — | 1 |
| Overactive urinary bladder | D053201 | EFO_1000781 | N32.81 | — | — | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Migraine disorders | D008881 | EFO_0003821 | G43 | 1 | — | — | — | — | 1 |
| Headache | D006261 | HP_0002315 | R51 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Castration-resistant prostatic neoplasms | D064129 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Diethylstilbestrol |
| INN | diethylstilbestrol |
| Description | Diethylstilbestrol is an olefinic compound that is trans-hex-3-ene in which the hydrogens at positions 3 and 4 have been replaced by p-hydroxyphenyl groups. It has a role as an antineoplastic agent, a carcinogenic agent, a xenoestrogen, an EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor, an antifungal agent, an endocrine disruptor, an EC 1.1.1.146 (11beta-hydroxysteroid dehydrogenase) inhibitor, an autophagy inducer and a calcium channel blocker. It is a polyphenol and an olefinic compound. |
| Classification | Small molecule |
| Drug class | estrogens |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC/C(=C(/CC)c1ccc(O)cc1)c1ccc(O)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 56-53-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL411 |
| ChEBI ID | 41922 |
| PubChem CID | 448537 |
| DrugBank | DB00255 |
| UNII ID | 731DCA35BT (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
ESRRB
ESRRB
ESR2
ESR2
Organism
Homo sapiens
Gene name
ESRRB
Gene synonyms
ERRB2, ESRL2, NR3B2
NCBI Gene ID
Protein name
steroid hormone receptor ERR2
Protein synonyms
ERR beta-2, ERR-beta, Estrogen receptor-like 2, estrogen-related nuclear receptor beta, Estrogen-related receptor beta, nuclear receptor ERRB2, Nuclear receptor subfamily 3 group B member 2, orphan nuclear receptor
Uniprot ID
Mouse ortholog
Esrrb (26380)
steroid hormone receptor ERR2 (Q61539)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 10,477 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
68 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use